Quarterly ResultMay 7, 2026, 07:03 AM
Lantheus Q1 Revenue $377.3M; FDA Approves PYLARIFY TruVu, PNT2003
AI Summary
Lantheus Holdings reported strong first-quarter 2026 results with worldwide revenue of $377.3 million, a 1.2% increase year-over-year. GAAP fully diluted EPS rose significantly by 76.5% to $1.80, while adjusted fully diluted EPS decreased by 4.6% to $1.46. The company secured FDA approval for PYLARIFY TruVu and tentative approval for Lutetium Lu 177 Dotatate (PNT2003). Lantheus also reaffirmed its full-year 2026 revenue and adjusted EPS guidance.
Key Highlights
- Worldwide revenue increased 1.2% to $377.3 million in Q1 2026.
- GAAP fully diluted EPS rose 76.5% to $1.80; adjusted fully diluted EPS decreased 4.6% to $1.46.
- FDA approved PYLARIFY TruVu, with a phased geographic launch planned for Q4 2026.
- FDA granted tentative approval for Lutetium Lu 177 Dotatate (PNT2003).
- PYLARIFY sales decreased 6.5% to $240.9 million; DEFINITY sales increased 6.8% to $84.6 million.
- Divestiture of the legacy SPECT business was completed on January 1, 2026.
- Reaffirmed full-year 2026 revenue guidance of $1.4 billion - $1.45 billion.
- Cash and cash equivalents were $498.6 million at March 31, 2026.